News in Brief
AudioCure Pharma gewinnt Innovationspreis Berlin Brandenburg 2024 mit ihrem neuen Wirkstoff AC102
Die AudioCure Pharma GmbH aus Berlin gewinnt mit ihrem neuartigen Wirkstoff AC102 den Innovationspreis Berlin Brandenburg 2024. Im Falle einer Zulassung als Medikament könnte AC102 einen wichtigen Fortschritt in der Behandlung des Hörsturzes darstellen, für den es bisher keine zugelassene und nachweislich wirksame Behandlungsoptionen gibt.
Sudden hearing loss study reaches milestone: AudioCure Pharma enrolls more than half of the patients in AC102 study
Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies.
Sudden Hearing Loss: AudioCure’s Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS
A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models. This is the key finding of a recent publication in the prestigious scientific journal PNAS by the Berlin-based start-up AudioCure Pharma.
Sudden Hearing Loss: Recent Clinical Trial HODOKORT Questions Benefits of Glucocorticoid Treatment
High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss. Moreover, they are associated with more side effects and significantly worse outcomes for speech recognition and tinnitus perception. Additionally, 60% of patients treated with the standard dose had not fully recovered by the end of the study.
AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2024 MidWinter Meeting in Anaheim (CA) on February 03-7 2024
AC102-201: A Phase 2 Clinical Trial Comparing the Efficacy of AC102, an Innovative Small Molecule, to Corticosteroids in Patients with Idiopathic Sudden Sensorineural Hearing Loss Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will present the AC102-201...
AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss
AudioCure is pleased to announce that it has been awarded for their innovative therapeutic small molecule, AC102, by the Hearing Technology Innovator Awards™, honoring technological innovation and accomplishments in the hearing industry.
Offene Veranstaltung: „Stand der Forschung und der aktuellen klinischen Studie“
AudioCure Pharma GmbH to attend upcoming ENT Congresses in Budweis (CZ)
České Budějovice, 31st May – 2nd June 2023: 84. Kongres České́ společnosti Otorinolaryngologie a chirurgie hlavy a krku ČLS JEP The Czech Society of Otorhinolaryngology and Head and Neck Surgery establishes recommended practices in the field and ensures...
AudioCure Pharma GmbH to attend upcoming ENT Congress in Leipzig (DE)
Leipzig, 18-20th May 2023 - 94. Jahresversammlung der DGHNO-KHC, Congress Center Leipzig The German Society of Oto-Rhino-Laryngology, Head and Neck Surgery is dedicated to the advancement of scientific and clinical knowledge in its fields. AudioCure CEO, Reimar...
AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2023 MidWinter Meeting in Orlando (FL) on February 11-15 2023
Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results about the effect of AC102 in a model of electrode insertion trauma at the ARO 2023 in Orlando. Moreover, Dr Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will talk about the results of a Phase I clinical trial with AC102 in healthy volunteers.